Provider Perspective on Integrative Medicine for Pediatric Sickle Cell Disease-related Pain

Caitlin M Neri1, Tishra Beeson2, Holly Mead3

  • 1Division of Pediatric Hematology, Boston Medical Center, Massachusetts; Department of Pediatrics, Boston University School of Medicine (Dr Neri), United States.

Insights

Provider perspectives on integrative medicine (IM) for pediatric sickle cell disease (SCD) pain are positive but underutilized. Barriers include lack of integration processes and inconsistent funding, highlighting a need for improved protocols and provider education.

Area of Science:

  • Integrative Medicine
  • Pediatric Hematology
  • Pain Management

Background:

  • Integrative medicine (IM) is explored for managing pain in pediatric sickle cell disease (SCD).
  • Understanding healthcare provider perspectives is crucial for effective implementation of IM in SCD care.

Purpose of the Study:

  • To explore provider views on using IM for pain in children with SCD.
  • To develop recommendations for enhancing IM promotion in pediatric SCD management.

Main Methods:

  • Qualitative case study design.
  • Criterion-type purposeful sampling of hematology providers.
  • Semistructured interviews analyzed using NVivo software.

Main Results:

  • Ten provider interviews revealed generally positive attitudes towards IM for SCD pain.
  • Providers identified a lack of integration processes and transient funding as key barriers.
  • Variable provider comfort levels and a desire for increased knowledge regarding IM were noted.

Conclusions:

  • Developing clear protocols for IM integration into SCD management plans is recommended.
  • Educating providers on IM's utility, efficacy, and available resources can promote its use for pediatric SCD pain.
Abstract

Related Concept Videos

Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
2.8K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
369
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
693
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
327
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
917
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
458